PDS Biotechnology Corp Repayments of Secured Debt
PDS Biotechnology Corp (PDSB) reported Repayments of Secured Debt of $2.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-08-13
- PDS Biotechnology Corp repayments of secured debt for the quarter ending 2026-06-30 was $1.00M, a 4.00% decline year-over-year.
- PDS Biotechnology Corp repayments of secured debt for the quarter ending 2026-03-31 was $1.50M, a 52.00% decline year-over-year.
- PDS Biotechnology Corp repayments of secured debt for the quarter ending 2025-12-31 was $1.50M, a 52.00% decline year-over-year.
- PDS Biotechnology Corp repayments of secured debt for the quarter ending 2025-09-30 was $1.00M.
- PDS Biotechnology Corp repayments of secured debt for fiscal 2025 was $6.67M, a 113.33% increase from fiscal 2024.
- PDS Biotechnology Corp repayments of secured debt for fiscal 2024 was $3.13M.
- PDS Biotechnology Corp repayments of secured debt for fiscal 2023 was $0.00.
- PDS Biotechnology Corp repayments of secured debt for fiscal 2018 was $20.00M.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.50M 10-Q · filed 2026-08-13 | $4.00M derived: sum of 3 quarters · filed 2026-08-13 | $5.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-14 | $3.00M derived: sum of 2 quarters · filed 2026-05-14 | $4.00M derived: sum of 3 quarters · filed 2026-05-14 | $5.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.50M derived: sum of 2 quarters · filed 2026-03-30 | $3.54M derived: sum of 3 quarters · filed 2026-08-13 | $6.67M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.04M derived: sum of 2 quarters · filed 2026-08-13 | $5.17M 10-Q · filed 2025-11-13 | $8.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.17M 10-Q · filed 2026-08-13 | $7.29M derived: sum of 3 quarters · filed 2026-08-13 | $7.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.13M 10-Q · filed 2026-05-14 | $6.25M derived: sum of 2 quarters · filed 2026-05-14 | $6.25M derived: sum of 3 quarters · filed 2026-05-14 | $6.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.13M derived: sum of 2 quarters · filed 2026-03-30 | $3.13M derived: sum of 3 quarters · filed 2026-03-30 | $3.13M 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $20.00M 10-K · filed 2019-02-21 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $20.00M 10-Q · filed 2018-11-01 | ||
| 2018-06-30 | $20.00M 10-Q · filed 2018-08-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 derived: sum of 3 quarters · filed 2019-02-21 | $0.00 10-K · filed 2019-02-21 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $0.00 10-Q · filed 2018-08-01 | $0.00 derived: sum of 3 quarters · filed 2018-08-01 | $381.60K derived: sum of 4 quarters · filed 2018-08-01 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-03 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $381.60K derived: sum of 3 quarters · filed 2018-03-01 | $941.42K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $381.60K derived: sum of 2 quarters · filed 2018-03-01 | $941.42K derived: sum of 3 quarters · filed 2018-03-01 | $1.49M 10-K · filed 2018-03-01 |
| 2016-09-30 | $381.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $941.42K derived: sum of 2 quarters · filed 2017-11-01 | $1.49M 10-Q · filed 2017-11-01 | $2.02M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $559.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $1.11M 10-Q · filed 2017-08-01 | $1.64M derived: sum of 3 quarters · filed 2018-03-01 | $1.64M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $547.14K 10-Q · filed 2017-05-03 | $1.08M derived: sum of 2 quarters · filed 2018-03-01 | $1.08M derived: sum of 3 quarters · filed 2018-03-01 | $1.08M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $533.73K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $533.73K derived: sum of 2 quarters · filed 2018-03-01 | $533.73K derived: sum of 3 quarters · filed 2018-03-01 | $533.73K 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2016-11-01 | $0.00 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $0.00 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-03 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |